Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

790
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
790
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

899
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
899
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

682
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
682
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

627
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
627
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.1K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence of aggregation-assisted antibacterial photodynamic activity against <i>S. aureus</i> and <i>E. coli</i> using amphiphilic Ru(II) polypyridyl complexes.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Visible-Light Sensitized Isomerization in the Lipid Bilayer Enables Activation of a Transmembrane Transporter.

Angewandte Chemie (International ed. in English)·2026
Same author

Ruthenium Complexes in Protein Science: Heading a New Generation of Therapeutic and Analytical Tools.

Angewandte Chemie (International ed. in English)·2025
Same author

A Sterically Open Ruthenium-Based Photocage Activated by Red and Far-Red Light for a Wide Range of Drugs.

Journal of the American Chemical Society·2025
Same author

Visualizing the Invisible: Dual Click Imaging of Ruthenium-Based Photoactivated Chemotherapy Agents and Their DNA Synthesis Inhibition in Fixed Cancer Cells.

Journal of the American Chemical Society·2025
Same author

Photoactivated Proximity Protein Labeling Reveals Enhanced Tumor Retention of a D-Peptide-Ruthenium Prodrug Conjugate.

Advanced healthcare materials·2025

Related Experiment Video

Updated: Feb 8, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Why develop photoactivated chemotherapy?

Sylvestre Bonnet1

  • 1Leiden Institute of Chemistry, Einsteinweg 55, 2333CC Leiden, The Netherlands. bonnet@chem.leidenuniv.nl.

Dalton Transactions (Cambridge, England : 2003)
|July 7, 2018
PubMed
Summary

Photoactivated chemotherapy (PACT) offers a promising approach for developing new bioactive compounds. This review advocates shifting from a compound-focused to a disease-focused strategy for greater clinical impact.

Area of Science:

  • Inorganic chemistry
  • Photochemistry
  • Oncology

Background:

  • Photoactivated chemotherapy (PACT) utilizes light-cleavable protecting groups to shield bioactive compounds until light activation.
  • PACT presents significant opportunities for novel inorganic compound development in medicine.
  • The clinical translation of PACT is hindered by a focus on chemical novelty over therapeutic needs.

Purpose of the Study:

  • To advocate for a paradigm shift in PACT research from a compound-based to a disease-based approach.
  • To discuss the advantages and disadvantages of PACT compared to other phototherapies.
  • To propose a roadmap for advancing PACT towards clinical applications.

Main Methods:

  • Literature review and critical analysis of the current PACT landscape.

More Related Videos

Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity
11:12

Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity

Published on: April 11, 2019

7.5K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 8, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity
11:12

Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity

Published on: April 11, 2019

7.5K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K
  • Comparative assessment of PACT with existing phototherapeutic modalities.
  • Strategic planning for future PACT development.

    • Main Results:

    • The PACT field has matured, enabling a transition to addressing specific clinical challenges.
    • A disease-based approach prioritizes therapeutic needs, guiding the design of PACT compounds.
    • PACT offers distinct advantages and disadvantages relative to other phototherapies.

    Conclusions:

    • A shift towards a disease-based approach is crucial for realizing the full clinical potential of PACT.
    • Future research should focus on developing PACT compounds tailored to specific diseases and patient needs.
    • Strategic roadmapping is essential for overcoming barriers to PACT clinical implementation.